We are live on ! Find out more
ERNA icon

Ernexa Therapeutics

32 hedge funds and large institutions have $78.5M invested in Ernexa Therapeutics in 2021 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 2 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,380% more capital inflows, than outflows

Capital inflows: $82.7M | Capital outflows: $720K

625% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 4

357% more funds holding

Funds holding: 7 → 32 (+25)

0.12% more ownership

Funds ownership: 10.09% → 10.21% (+0.12%)

57% less call options, than puts

Call options by funds: $3.96M | Put options by funds: $9.29M

Holders
32
Holders Change
+25
Holders Change %
+357.14%
% of All Funds
0.55%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
29
Increased
2
Reduced
–
Closed
4
Calls
$3.96​M
Puts
$9.29​M
Net Calls
-⁠$5.32​M
Net Calls Change
-⁠$5.32​M

ERNA Hedge Fund Activity: Q2 2021 in Review

32 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Ernexa Therapeutics (ERNA) for Q2 2021, worth a combined $78.5M — up 14,050% from $555K a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new ERNA positions and 4 closed out — a net gain of 25 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $26.9M. The largest seller was Citadel Advisors, exiting entirely with an estimated $432K sold.

  • 32 institutional investors held Ernexa Therapeutics (ERNA) as of Q2 2021, up from 7 in Q1 2021.
  • Funds reported $78.5M of Ernexa Therapeutics stock for Q2 2021, up 14,050% quarter-over-quarter.
  • 29 funds opened new Ernexa Therapeutics positions in Q2 2021 and 4 closed out, a net change of +25 holders.
  • The largest Ernexa Therapeutics buyer in Q2 2021 was BlackRock, an estimated $26.9M added.
  • The largest Ernexa Therapeutics seller in Q2 2021 was Citadel Advisors, an estimated $432K sold.

Based on aggregated 13F filings for Q2 2021.